EWTX:NASDAQEdgewise Therapeutics, Inc. Analysis
Data as of 2026-04-01 - not real-time
$33.14
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Edgewise Therapeutics is trading at $33.14, comfortably above its 20‑day SMA (30.18) and 50‑day SMA (29.75), with the 200‑day SMA (20.63) far below, confirming a strong bullish trend. Momentum indicators reinforce this view – the RSI sits at 63.6 (still below overbought) and the MACD histogram is positive, while the price is hovering just below the key resistance level of $33.47.
The stock carries a high volatility of 44% over the past 30 days and a beta above 1, indicating sensitivity to market swings, yet it benefits from a solid cash position ($530M) and minimal debt. Analyst sentiment is positive (12 analysts, median target $45, implied upside ~24%), and recent material news highlights encouraging long‑term data for sevasemten and upcoming Phase III readouts, providing near‑term catalysts despite the company’s current lack of revenue and negative earnings.
The stock carries a high volatility of 44% over the past 30 days and a beta above 1, indicating sensitivity to market swings, yet it benefits from a solid cash position ($530M) and minimal debt. Analyst sentiment is positive (12 analysts, median target $45, implied upside ~24%), and recent material news highlights encouraging long‑term data for sevasemten and upcoming Phase III readouts, providing near‑term catalysts despite the company’s current lack of revenue and negative earnings.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish technical setup with price above short‑term averages
- Upcoming clinical readout for sevasemten Becker data
- Analyst consensus indicating upside of ~24%
Medium Term
1–3 yearsNeutral
Model confidence: 8/10
Key Factors
- Potential Phase III results and HCM data in Q2
- Strong cash runway versus modest market cap
- Continued high volatility and beta requiring careful position sizing
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Large addressable market for muscular dystrophy and cardiac indications
- Pipeline diversification beyond sevasemten
- Long‑term upside potential reflected in analyst target prices
Key Metrics & Analysis
Financial Health
P/E Ratio-14.2
ROE-34.19%
ROA-23.02%
Debt/Equity0.76
P/B Ratio6.7
Op. Cash Flow$-143816000
Free Cash Flow$-87337752
Industry P/E25.8
Technical Analysis
TrendBullish
RSI63.6
Support$26.82
Resistance$33.47
MA 20$30.18
MA 50$29.75
MA 200$20.63
MACDBullish
VolumeStable
Fear & Greed Index77.61
Valuation
Target Price$41.08
Upside/Downside23.97%
GradeFair
TypeGrowth
Risk Assessment
Beta1.28
Volatility43.97%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.